Гігантські аденоми гіпофіза: поширеність, особливості діагностики і клінічного перебігу

YM Urmanova, KB Alimova - INTERNATIONAL JOURNAL OF …, 2018 - iej.zaslavsky.com.ua
Based on the review of the literature, it is established that in the diagnostic complex with
giant pituitary adenomas, in addition to clinical examination, it is necessary to use a full …

[PDF][PDF] initiation and progression [version 1; peer review: 2 approved]

U Renner, D Ciato, GK Stalla - 2018 - pdfs.semanticscholar.org
Cushing's disease is the most frequent form of hypercortisolism and is caused by
hypophyseal corticotroph adenomas secreting excessive amounts of adrenocorticotropic …

Growth and Aggressiveness in Clinically Non-Functioning Pituitary Adenomas

KAB Øystese - 2018 - duo.uio.no
Clinically non-functioning pituitary adenomas (NFPAs) are tumours originating from the
anterior pituitary, without clinical symptoms of uncontrolled hormone overproduction. These …

[HTML][HTML] Macroprolactinoma causing VI, X, XII cranial nerve palsies nearly 30 years after initial treatment

A De Bray, ZK Hassan-Smith, J Dirie… - … & metabolism case …, 2018 - edm.bioscientifica.com
A 48-year-old man was diagnosed with a large macroprolactinoma in 1982 treated with
surgery, adjuvant radiotherapy and bromocriptine. Normal prolactin was achieved in 2005 …

Pretkazatelji kliničkoga ponašanja adenoma hipofize [Predictors of clinical behavior of pituitary adenomas]

M Solak - 2018 - medlib.mef.hr
Hipofiza je žlijezda smještena na bazi lubanje u području sfenoidnog sinusa koji se naziva
tursko sedlo (engl. sella turcica). Sastoji se od prednjeg režnjaadenohipofize, stražnjeg …

Pituitary adenomas—not always benign

S Petersenn - Der Onkologe, 2018 - Springer
Zusammenfassung Hintergrund Mit einer Prävalenz von 80–100 Fällen pro 100.000
Einwohner sind Hypophysenadenome häufiger als allgemein angenommen. Meist werden …

Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions

LV Syro Moreno, F Rotondo, M Camargo Guerrero… - 2018 - bibliotecadigital.udea.edu.co
Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded
to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable …